Aliskiren (Speedel).
Speedel Pharma is developing aliskiren (formerly CGP-60536), a renin inhibitor under license from Novartis, for the potential treatment of several cardiovascular disorders. By October 2001, a phase IIb study in hypertension had been completed, and phase III studies for this indication were anticipated for 2002; at this time, phase II studies in congestive heart failure and chronic renal failure were ongoing.